Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 1.00 |
| ▸ | SCARB1 | Q8WTV0 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimcazole SCHEMBL29710924 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL99084 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL31395408 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL6257536 | 0.98 | SIGMAR1 (0.97) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL7410252 | 0.98 | SIGMAR1 (0.97) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL122161 | 0.98 | SIGMAR1 (0.97) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL7411898 | 0.97 | MEN1 (1.00) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL7411904 | 0.97 | MEN1 (1.00) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL3627653 | 0.97 | MEN1 (1.00) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL7414121 | 0.92 | SIGMAR1 (0.85) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180256720-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-09-13 | — | — | US | claimed |
| WO-2010015040-A1 | THERAPY AND PREVENTION OF TDP-43 PROTEINOPATHY | POWMRI LTD (AU) | 2010-02-11 | — | — | WO | claimed |
| WO-2025031979-A1 | USE OF RIMCAZOLE TO TREAT CANCER | KYREXA LTD (GB) | 2025-02-13 | — | — | WO | disclosed |
| US-20180256720-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-09-13 | — | — | US | disclosed |
| EP-2874997-A2 | NOVEL SIGMA RECEPTOR LIGANDS AND METHODS OF MODULATING CELLULAR PROTEIN HOMEOSTASIS USING SAME | Drexel University (US) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014015157-A2 | NOVEL SIGMA RECEPTOR LIGANDS AND METHODS OF MODULATING CELLULAR PROTEIN HOMEOSTASIS USING SAME | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2014-01-23 | — | — | WO | disclosed |
| EP-1091759-B1 | COMPOSITION FOR THE INDUCTION OF APOPTOSIS IN TARGET CELLS | UNIV DUNDEE (GB) | 2012-10-24 | — | — | EP | disclosed |
| US-20100292249-A1 | MANUFACTURE OF RIMCAZOLE | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-11-18 | — | — | US | disclosed |
| WO-2010128309-A1 | COMBINATION THERAPY COMPRISING A TAXANE AND A SIGMA RECEPTOR LIGAND SAUCH AS RIMCAZOLE | MODERN BIOSCIENCES, PLC. (GB) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010058166-A1 | USE OF RIMCAZOLE FOR THE TREATMENT OF OCULAR DISORDERS | MODERN BIOSCIENCES PLC (GB) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010058166-A1 | USE OF RIMCAZOLE FOR THE TREATMENT OF OCULAR DISORDERS | MODERN BIOSCIENCES PLC (GB) | 2010-05-27 | — | — | WO | disclosed |
| US-5086054-A | Selective high-affinity ligands to sigma boding sites, administering, amipsychotic, antiarrhythmia, antiischemic agents anticonvulsants, reduced side effects | SRI INTERNATIONAL (US) | 1992-02-04 | — | — | US | disclosed |
| US-4588728-A | Treatment of drug induced psychosis | BURROUGHS WELLCOME CO. (US) | 1986-05-13 | — | — | US | disclosed |
| US-4588728-A | Treatment of drug induced psychosis | BURROUGHS WELLCOME CO. (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0051321-B1 | CIS-DIMETHYLPIPERAZINES FOR THE PREPARATION OF N-SUBSTITUTED CARBAZOLES | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-03-26 | — | — | EP | disclosed |
| US-4400383-A | 9-(3-(3,5-CIS-DIMETHYLPIPERAZINO/PROPYL)CARBAZOLE | BURROUGHS WELLCOME CO. (US) | 1983-08-23 | — | — | US | disclosed |
| US-4379160-A | Carbazole compounds and medicinal use thereof | BURROUGHS WELLCOME CO. (US) | 1983-04-05 | — | — | US | disclosed |
| EP-0012208-B1 | 9-(3-(3,5-CIS-DIMETHYLPIPERAZINO)PROPYL)-CARBAZOLE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-01-26 | — | — | EP | disclosed |
| EP-0051321-A1 | Cis-dimethylpiperazines for the preparation of N-substituted carbazoles | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-05-12 | — | — | EP | disclosed |
| EP-0012208-A2 | 9-(3-(3,5-cis-Dimethylpiperazino)propyl)-carbazole, its preparation and pharmaceutical compositions containing it | THE WELLCOME FOUNDATION LIMITED (GB) | 1980-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292249-A1 | MANUFACTURE OF RIMCAZOLE | P2RX5, CYP3A5, ADRA2C | SIGMAR1 360/4885SCARB1 2298/4885MEN1 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.